Guobang Pharma Ltd (605507) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.038x

Based on the latest financial reports, Guobang Pharma Ltd (605507) has a cash flow conversion efficiency ratio of 0.038x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥311.27 Million ≈ $45.55 Million USD) by net assets (CN¥8.28 Billion ≈ $1.21 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 605507 stock market capitalisation for the company's overall valuation and market capitalisation.

Guobang Pharma Ltd - Cash Flow Conversion Efficiency Trend (2017–2025)

This chart illustrates how Guobang Pharma Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Guobang Pharma Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Guobang Pharma Ltd ranked by their cash flow conversion efficiency. Explore 605507 operating cash flow to net income to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Shenzhen Hymson Laser Intelligent Equipments Co Ltd SHG:688559	0.057x
Sapiens International Corporation NV TA:SPNS	0.020x
INTERNET IN.JP.ADR 1 ON F:IIJ	0.110x
Beijing Zhong Ke San Huan High-Tech Co Ltd SHE:000970	0.007x
Zhejiang Jiuzhou Pharm Co Ltd SHG:603456	0.055x
UroGen Pharma Ltd NASDAQ:URGN	0.249x
Sineng Electric Co Ltd SHE:300827	-0.028x
Weifu High-Technology Group Co Ltd SHE:000581	0.049x

Annual Cash Flow Conversion Efficiency for Guobang Pharma Ltd (2017–2025)

The table below shows the annual cash flow conversion efficiency of Guobang Pharma Ltd from 2017 to 2025. View 605507 stock price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥8.56 Billion ≈ $1.25 Billion	CN¥559.28 Million ≈ $81.84 Million	0.065x	-25.49%
2024-12-31	CN¥8.05 Billion ≈ $1.18 Billion	CN¥706.41 Million ≈ $103.37 Million	0.088x	+26.26%
2023-12-31	CN¥7.44 Billion ≈ $1.09 Billion	CN¥516.76 Million ≈ $75.62 Million	0.069x	-51.12%
2022-12-31	CN¥7.15 Billion ≈ $1.05 Billion	CN¥1.02 Billion ≈ $148.82 Million	0.142x	+611.99%
2021-12-31	CN¥6.35 Billion ≈ $928.57 Million	CN¥-176.18 Million ≈ $-25.78 Million	-0.028x	-111.84%
2020-12-31	CN¥3.27 Billion ≈ $479.11 Million	CN¥767.70 Million ≈ $112.34 Million	0.234x	+39.13%
2019-12-31	CN¥2.62 Billion ≈ $382.78 Million	CN¥440.86 Million ≈ $64.51 Million	0.169x	-19.35%
2018-12-31	CN¥2.59 Billion ≈ $379.31 Million	CN¥541.68 Million ≈ $79.27 Million	0.209x	+211.60%
2017-12-31	CN¥2.21 Billion ≈ $323.00 Million	CN¥148.03 Million ≈ $21.66 Million	0.067x	--

About Guobang Pharma Ltd

SHG:605507 China Drug Manufacturers - Specialty & Generic

Market Cap

$2.09 Billion

CN¥14.29 Billion CNY

Market Cap Rank

#6062 Global

#1167 in China

Share Price

CN¥18.26

Change (1 day)

+1.16%

52-Week Range

CN¥14.70 - CN¥29.25

All Time High

CN¥43.71